Lazari Capital Management Inc. Has $320,000 Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Lazari Capital Management Inc. decreased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,508 shares of the company’s stock after selling 1,102 shares during the quarter. Lazari Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $320,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TEVA. Diversify Advisory Services LLC boosted its stake in Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after acquiring an additional 496 shares during the last quarter. Sanctuary Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after buying an additional 664 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after buying an additional 805 shares in the last quarter. DGS Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after buying an additional 872 shares in the last quarter. Finally, Smithfield Trust Co lifted its stake in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $17.81 on Monday. Teva Pharmaceutical Industries Limited has a 12-month low of $11.62 and a 12-month high of $22.80. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock’s 50 day simple moving average is $20.00 and its 200 day simple moving average is $18.50.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 40.20% and a negative net margin of 9.91%. Research analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Barclays dropped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $22.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.